Clearside Biomedicals Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications -
Suprachoroidal injection has emerged as a promising method for delivering drugs directly to the target site in the eye, offering significant advantages over traditional delivery methods. Clearside Biomedical, a leading biopharmaceutical company specializing in developing and commercializing therapies for sight-threatening diseases, continues to showcase its expertise in suprachoroidal delivery. The company’s latest achievements were highlighted in multiple presentations at the Clinical Trials at the Summit Meeting, demonstrating their leadership and significant contributions to the field.
Clearside Biomedical’s groundbreaking suprachoroidal injection platform allows for the targeted delivery of therapeutic agents to the back of the eye, specifically the retina and choroid, where many chronic ocular diseases manifest. This unique approach involves accessing the suprachoroidal space, which lies between the sclera and the choroid, enabling the direct administration of medication precisely to the affected areas. By bypassing the traditional barriers, such as the blood-retinal barrier, and avoiding invasive procedures like vitreous injections, Clearside’s method offers a safer and more efficient treatment option for retinal indications.
During the Clinical Trials at the Summit Meeting, Clearside Biomedical’s leadership in suprachoroidal delivery was underlined through numerous presentations, showcasing the broad use of their platform across multiple retinal indications. The results from various clinical trials demonstrated the effectiveness of the suprachoroidal injection platform in treating diseases such as uveitis, macular edema associated with non-infectious posterior uveitis, and diabetic macular edema (DME). The positive outcomes obtained from these trials reinforce the potential of Clearside’s platform to revolutionize the treatment landscape for patients suffering from debilitating ocular conditions.
One notable presentation focused on Clearside Biomedical’s phase 3 clinical trial, known as the PEACHTREE study, evaluating suprachoroidal CLS-TA (triamcinolone acetonide) in patients with macular edema associated with non-infectious uveitis. The trial demonstrated significant improvements in visual acuity and central subfield thickness, indicating the remarkable efficacy of their suprachoroidal injection platform in alleviating the burden of uveitis-associated macular edema.
Additionally, Clearside’s suprachoroidal injection platform was highlighted in another presentation discussing the TYBEE study, which investigated the use of suprachoroidal CLS-TA in patients with diabetic macular edema. The findings from this study indicated meaningful improvements in visual acuity and anatomical parameters, emphasizing the potential of suprachoroidal delivery as a viable treatment option for individuals with DME.
The breadth of evidence showcased during the Clinical Trials at the Summit Meeting solidifies Clearside Biomedical’s leadership in the field of suprachoroidal delivery. By consistently demonstrating the safety and efficacy of their platform across various retinal indications, Clearside’s pioneering approach holds immense promise for transforming the treatment landscape for sight-threatening diseases. The company’s dedication to advancing the field of ocular therapeutics and improving patients’ lives is evident in their pioneering contributions and unwavering commitment to innovation.
Comments